ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

ZYNLONTA^® plus glofitamab (COLUMVI^®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL

Safety and tolerability data were consistent with the known profiles of each agent

Read more at prnewswire.com